Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14701462 | 0.89 | TACR1 (0.49) | TACR1TGFBR1MEN1KMT2ATEAD1 | |
| SCHEMBL12415412 | 0.86 | ALDH1A1 (0.41) | TACR1MEN1KMT2APOLB | |
| SCHEMBL18280017 | 0.84 | TGFBR1 (0.53) | TACR1TGFBR1STSMEN1KMT2A | |
| SCHEMBL20015333 | 0.83 | MAOB (0.57) | TACR1TGFBR1STSMEN1KMT2A | |
| SCHEMBL14701440 | 0.83 | RBP4 (0.52) | MEN1KMT2APOLB | |
| SCHEMBL4306665 | 0.82 | MEN1 (0.51) | TACR1TGFBR1STSMEN1KMT2A | |
| SCHEMBL20566961 | 0.82 | TEAD1 (0.63) | TACR1TGFBR1STSGPR119TEAD1 | |
| SCHEMBL31414500 | 0.81 | KMT2A (0.63) | TACR1STSMEN1KMT2ATEAD1 | |
| SCHEMBL14701443 | 0.81 | GPR119 (0.58) | TACR1TGFBR1STSGPR119POLB | |
| SCHEMBL4307807 | 0.81 | MEN1 (0.56) | TACR1TGFBR1STSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | TACR1 889/4885TGFBR1 1081/4885STS 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.